期刊
PEDIATRIC CLINICS OF NORTH AMERICA
卷 62, 期 1, 页码 121-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.pcl.2014.09.009
关键词
Down syndrome; Preleukemia; Leukemia; Myeloid leukemia of Down syndrome; B-ALL; GATA1; Transient abnormal hematopoiesis/transient myeloproliferative disorder
类别
资金
- MRC [MC_UU_12009/14] Funding Source: UKRI
- Medical Research Council [MC_UU_12009/14] Funding Source: researchfish
- Medical Research Council [G1000729, MR/L008963/1, MC_UU_12009/11, MC_UU_12009/14] Funding Source: Medline
Children with Down syndrome (DS) and acute leukemias acute have unique biological, cytogenetic, and intrinsic factors that affect their treatment and outcome. Myeloid leukemia of Down syndrome (ML-DS) is associated with high event-free survival (EFS) rates and frequently preceded by a preleukemia condition, the transient abnormal hematopoiesis (TAM) present at birth. For acute lymphoblastic leukemia (ALL), their EFS and overall survival are poorer than non-DS ALL, and it is important to enroll them on therapeutic trials, including relapse trials; investigate new agents that could potentially improve their leukemia-free survival; and strive to maximize the supportive care these patients need.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据